MAR 23, 2019 9:13 PM PDT

New Drug Therapeutic for Portal Hypertension

WRITTEN BY: Nouran Amin

According to a study published in the journal of the American Gastroenterological Association, drug therapy, called sivelestat, may effectively treat life-threatening liver diseases such as those associated with cirrhosis and in particular lower portal hypertension.

Results of the study concluded by Mayo Clinic researchers have showed that sivelestat, in mouse models and human liver samples, improved symptoms and outcomes for liver disease patients. "This was an exciting confirmation of our findings and their applicability to human disease" says, Dr. Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author. "Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease."

Current therapeutics are available for certain forms of liver disease, such as hepatitis C and autoimmune hepatitis, however treatments have been limited for treating portal hypertension--a condition associated with cirrhosis and other chronic liver diseases and characterized by an increase in pressure within the portal vein that carries blood from abdominal organs to the liver.

"The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces," says Dr. Moira Hilscher M.D., the paper's first author. "Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need."

Specifically, the study showed that sivelestat decreases portal hypertension through the inhibition of the neutrophil function. Neutrophils are critical cells of the immune system that are involved in producing microvascular blood clots known as fibrin which in turn contributes portal hypertension. "Neutrophils had not previously been identified as significant drivers of portal hypertension," says Hilscher.

Results of the study were illustrated in two models of chronic liver disease.

Source: Mayo Clinic

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 07, 2020
Cancer
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
OCT 07, 2020
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
Over the years, cancer researchers have struggled not just with drug and diagnostic design, but with drug delivery. The ...
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
OCT 22, 2020
Neuroscience
Placebos Impact Brain Patterns for Emotional Processing
OCT 22, 2020
Placebos Impact Brain Patterns for Emotional Processing
Researchers from Michigan State University have found that placebos reduce markers of emotional distress- even when the ...
OCT 29, 2020
Cardiology
Treating Cardiovascular Calcification at the Source
OCT 29, 2020
Treating Cardiovascular Calcification at the Source
The term cardiovascular disease covers a broad array of health problems. Everyone tends to think of heart attacks or hyp ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
Loading Comments...